Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
New Microbiol ; 45(4): 260-268, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36190370

ABSTRACT

Diagnosis and management of infectious diseases (ID) at the emergency department (ED) are challenging due to the peculiar setting and the available diagnostic tools. The involvement of an ID consultant has been described to improve clinical outcomes and antimicrobial stewardship (AMS) programs. An online survey was sent to 100 Italian Departments of Infectious Diseases affiliated with the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT). The primary objective of our study was to describe the characteristics of ID services in Italian EDs to identify possible challenges and shortcomings and provide tips to improve the management of patients. Secondary objectives included the evaluation of diagnostic capability and the management of patients with suspected or confirmed ID. Seventy-six out of the 100 SIMIT centers, 32 (42.1%) of which were teaching hospitals, answered the survey. In 62 (82.7%) centers, consultations were performed by the IDs specialist on call. In 29 (38.2%) centers, there was a formal AMS program, and 32 (42.7%) had protocols for antibiotic use in the ED. Microbiological tests to be performed before starting antibiotic treatment in the ED were clearly defined in 44 (57.9%) hospitals. This survey highlighted several challenges in the current organization of ID consultations in Italian EDs.


Subject(s)
Communicable Diseases , Humans , Communicable Diseases/diagnosis , Communicable Diseases/drug therapy , Communicable Diseases/epidemiology , Emergency Service, Hospital , Anti-Bacterial Agents/therapeutic use , Referral and Consultation , Italy/epidemiology , Hospitals, Teaching
2.
Infection ; 48(2): 249-258, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31893354

ABSTRACT

PURPOSE: Recommended regimens for pregnant women with HIV-1 are composed of two nucleoside reverse transcriptase inhibitors (NRTI) plus either a ritonavir-boosted protease inhibitor (PI) or an integrase strand transfer inhibitor (ISTI), with non-nucleoside reverse transcriptase inhibitors (NNRTI) representing an alternative drug class. The study's purpose was to compare these three options in terms of pregnancy outcomes. METHODS: Data from a national observational study of pregnant women with HIV-1 were used. The analysis included all pregnancies reported between 2008 and 2018, ending in live births and exposed within 32 weeks of gestation to three-drug regimens composed of a NRTI backbone plus a PI, a NNRTI or a ISTI, without class switching during pregnancy. Clinical and laboratory outcomes were evaluated in univariate and multivariable analyses. RESULTS: Overall, 794 exposed pregnancies were analyzed (PI 78.4%, NNRTI 15.4%, ISTI 6.2%). Almost all outcomes had similar rates in the three groups. Women who received PI in pregnancy were less likely to be virologically suppressed at third trimester. PI use was associated with higher bilirubin and triglyceride levels, and ISTI use with a lower rate of low birthweight. The differences in viral suppression at third trimester and in low birthweight were not maintained in multivariable analyses that were adjusted for confounders. DISCUSSION: We found no major differences in a wide range of outcomes relevant for pregnant women with HIV. Such results are reassuring, and this information may be helpful in a context of preconception counseling when therapeutic choices for pregnancy are discussed between women and care providers.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Integrase Inhibitors/therapeutic use , Protease Inhibitors/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adult , Anti-HIV Agents/adverse effects , Birth Weight , Female , HIV-1 , Humans , Integrase Inhibitors/adverse effects , Multivariate Analysis , Pregnancy , Pregnancy Outcome , Protease Inhibitors/adverse effects , RNA, Viral/blood , Reverse Transcriptase Inhibitors/adverse effects
3.
New Microbiol ; 39(4): 241-246, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27727402

ABSTRACT

It is crucial to establish the timing of infection and distinguish between early and long-lasting HIV-1 infections not only for partner notification and epidemiological surveillance, but also to offer early drug treatment and contain the spread of infection. This study analyzed serum and/or plasma samples with a first positive HIV antibody/antigen result coming from different Medical Centers in the Emilia Romagna Region, North East Italy, using the avidity assay, Western Blotting, RNA viral load, CD4 cell counts and genotyping assay. From May 2013 to May 2016, we certified 845 new HIV-1 infections, 18.7% of which were classified on the basis of avidity index as recent infections and 81.3% as long-lasting infections, with an estimated conversion time exceeding six months at the time of study. Western Blotting showed reactivity to only one or two HIV-1 proteins in recently infected patients (RIPs), while a complete pattern to gag, env and pol proteins was observed in most long-lasting infected patients (LLIPs). The median age, gender, nationality and risk transmission factors were comparable in RIPs and LLIPs. Phylogenetic analysis performed in available plasma disclosed B strains, non-B subtypes and circulating recombinant forms (CRFs) in both groups of patients, with a major presence of CRFs in non-Italian HIV subjects. The large number of patients unaware of their HIV status makes it crucial to discover hidden epidemics and implement appropriate targeted public health interventions.


Subject(s)
HIV Infections/diagnosis , HIV-1 , Adult , Aged , CD4 Lymphocyte Count , Female , HIV Infections/epidemiology , HIV Infections/transmission , HIV-1/genetics , Homosexuality, Male , Humans , Italy/epidemiology , Male , Middle Aged , Phylogeny , RNA, Viral/blood , Substance Abuse, Intravenous , Viral Load , pol Gene Products, Human Immunodeficiency Virus/genetics
4.
HIV Clin Trials ; 14(3): 110-9, 2013.
Article in English | MEDLINE | ID: mdl-23835513

ABSTRACT

BACKGROUND: There is limited information on pregnancy outcomes in women with HIV who are of a more advanced maternal age. METHODS: Data from a national observational study in Italy were used to evaluate the risk of nonelective cesarean section, preterm delivery, low birthweight, major birth defects, and small gestational age-adjusted birthweight according to maternal age (<35 and ≥35 years, respectively). RESULTS: Among 1,375 pregnancies with live births, 82.4% of deliveries were elective cesarean sections, 15.8% were nonelective cesarean sections, and 1.8% were vaginal deliveries. Rates of nonelective cesarean section were similar among mothers ≥35 and <35 years (odds ratio [OR], 1.22; 95% CI, 0.90-1.65;P = .19). Preterm delivery and low birthweight were significantly more common among women ≥35 years in univariate but not in multivariate analyses. Newborns from women ≥35 and <35 years showed no differences inZ scores of birthweight, with a similar occurrence of birthweight <10th percentile (12.1% vs 12.0%; OR, 1.02; 95% CI, 0.71-1.46;P = .93). The overall rate of birth defects was 3.4% (95% CI, 2.4-4.4), with no differences by maternal age (≥35 years, 3.5%; <35 years, 3.3%; OR, 1.05; 95% CI, 0.56-1.98;P = .88). DISCUSSION: In this study of pregnant women with HIV, older women were at higher risk of some adverse pregnancy outcomes, such as preterm delivery and low birthweight. The association, however, did not persist in multivariable analyses, suggesting a role of some predisposing factors associated with older age.


Subject(s)
HIV Infections/complications , Maternal Age , Pregnancy Complications, Infectious/virology , Pregnancy Outcome , Adult , Female , Humans , Logistic Models , Multivariate Analysis , Pregnancy
5.
Infect Dis (Lond) ; 50(5): 352-360, 2018 05.
Article in English | MEDLINE | ID: mdl-29210336

ABSTRACT

BACKGROUND: The ritonavir-boosted protease inhibitor (PI/r)-based dual regimens are warranted in order to optimize the combination antiretroviral therapy (cART), prevent the long-term toxicity and reduce the cost of treatments. METHODS: We performed an observational, retrospective study of HIV-infected patients on suppressive antiretroviral therapy who switched to a dual regimen containing lamivudine (3TC) plus darunavir/ritonavir (DRV/r) 800/100 mg qd or atazanavir/ritonavir (ATV/r) 300/100 mg qd. RESULTS: As a whole, 122 well-treated patients (mean age, 45.2 years; mean CD4 T + lymphocyte count, 589 cells/mm3; mean duration of current cART, 3.1 years) were enrolled. Current antiretroviral regimen included tenofovir/emtricitabine in 91 subjects, abacavir/lamivudine in 25, lopinavir/r in 41, DRV/r in 38 and ATV/r in 33. Baseline mean estimated glomerular filtration rate (eGFR) was 94.2 mL/min/1.73 m2, and proteinuria was detected in 46 subjects (38%). Overall 70 subjects switched to 3TC + DRV/r (group A) and 52 to 3TC + ATV/r (group B). After 12 months, 65 patients (92.8%) in group A and 46 (88.4%) in group B showed HIV RNA <20 copies/mL. A significant and comparable increase in eGFR was observed in group A and B (+3.8 and +3.1 mL/min/1.73 m2, respectively), such as a significant decrease in prevalence of proteinuria. A significantly greater increase in total bilirubin concentration was reported in group B than in group A. CONCLUSION: In our study, simplification to a dual therapy containing 3TC + DRV/r or ATV/r in virologically suppressed patients was effective and showed a good tolerability profile.


Subject(s)
Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/methods , Drug Therapy, Combination/methods , HIV Infections/drug therapy , Reverse Transcriptase Inhibitors/therapeutic use , Viral Load/drug effects , Adult , Anti-HIV Agents/administration & dosage , Atazanavir Sulfate/administration & dosage , Atazanavir Sulfate/therapeutic use , CD4 Lymphocyte Count , Cohort Studies , Darunavir/administration & dosage , Darunavir/therapeutic use , Female , HIV Infections/virology , HIV-1/drug effects , Humans , Lamivudine/administration & dosage , Lamivudine/therapeutic use , Male , Middle Aged , Retrospective Studies , Reverse Transcriptase Inhibitors/administration & dosage , Ritonavir/administration & dosage , Ritonavir/therapeutic use
6.
HIV Clin Trials ; 18(2): 54-59, 2017 03.
Article in English | MEDLINE | ID: mdl-28067163

ABSTRACT

OBJECTIVE: To evaluate the impact of Hepatitis B virus (HBV) coinfection on response to antiretroviral treatment in pregnant women with HIV. METHODS: Retrospective analysis of a large case series of pregnant women with HIV in Italy; outcome measures were CD4 changes, HIV viral load, and main pregnancy outcomes (preterm delivery, low birthweight, intrauterine growth restriction, mode of delivery, and major birth defects). RESULTS: Rate of HBV coinfection among 1462 pregnancies was 12.0%. Compared to the HBV-uninfected, HBV-coinfected women had a significantly lower median CD4 cell gain between first and third trimester (26.5 vs. 60 cells/mm3, p = 0.034), with similar rate of undetectable (<50 copies/ml) HIV-RNA at third trimester (70.5% vs. 65.2%, p = 0.229), and no differences in all the main maternal and infant outcomes. A multivariable linear regression analysis identified four variables significantly and independently associated with a lower CD4 response in pregnancy: HBV coinfection (-35 cells/mm3), being on antiretroviral treatment at conception (-59.7 cells/mm3), AIDS status (-59.8 cells/mm3) and higher first CD4 levels in pregnancy (-0.24 cells per unitary CD4 increase). CONCLUSIONS: HBV coinfection had no adverse influence on the main pregnancy outcomes or on HIV viral load suppression in late pregnancy but was associated with a significantly reduced CD4 response in pregnancy. This effect might have clinical relevance, particularly in women with advanced immune deterioration.


Subject(s)
Antiretroviral Therapy, Highly Active , CD4-Positive T-Lymphocytes/immunology , Coinfection , HIV Infections/drug therapy , HIV Infections/immunology , Hepatitis B/immunology , Adult , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/metabolism , Female , HIV Infections/epidemiology , HIV Infections/virology , Hepatitis B/epidemiology , Hepatitis B virus/immunology , Humans , Infant , Italy/epidemiology , Odds Ratio , Pregnancy , Pregnancy Outcome , Treatment Outcome , Viral Load
7.
Acta Biomed ; 86(2): 200-4, 2015 Sep 14.
Article in English | MEDLINE | ID: mdl-26422438

ABSTRACT

Major trauma represents a paradigmatic clinical condition, needing multidisciplinary and structured approach. When a patient is affected by significant comorbidities such as diabetes mellitus and other conditions that compromise the immune competence the risk of infections in the presence of exposed fractures is remarkably high. Although usually managed by multidisciplinary teams, these patients often have unfavorable functional outcomes. We describe here the case of a young diabetic and immunosuppressed man, treated for a destroying injury of the left lower limb, with more than 60 centimeters of multiple fractures exposition. The prompt and fast integration of several different competences led to favorable functional outcome, without any severe local or systemic complication. Therefore, in severely injured patients, especially when affected by significant comorbidities, a quick and highly integrated treatment, provided by a polyspecialistic team, is crucial for reducing unfavorable outcomes and improving the recovery rate.


Subject(s)
Diabetes Mellitus, Type 2/complications , Fracture Fixation/methods , Hypoglycemic Agents/therapeutic use , Leg Injuries/complications , Multiple Trauma/complications , Adult , Diabetes Mellitus, Type 2/therapy , Femoral Fractures/complications , Femoral Fractures/diagnosis , Femoral Fractures/therapy , Fibula/injuries , Humans , Leg Injuries/diagnosis , Leg Injuries/therapy , Male , Multiple Trauma/diagnosis , Multiple Trauma/therapy , Patella/injuries , Tibial Fractures/complications , Tibial Fractures/diagnosis , Tibial Fractures/therapy , Trauma Severity Indices
SELECTION OF CITATIONS
SEARCH DETAIL